# Matinas Biopharma Holdings Inc. (MTNB)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $3M  
**Price:** $0.80 (-0.25%)

> Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for unmet medical needs. Its primary function lies in the creation and advancement of lipid nano-crystal delivery technology, which aims to enhance the bioavailability and efficacy of pharmaceuticals. This company has a strategic focus on infectious diseases and rare disorders, addressing significant gaps in existing therapeutic options. Matinas Biopharma's innovative delivery platforms are designed to optimize drug exposure, enhance safety profiles, and enable oral dosing of complex molecules, which can potentially transform the treatment landscape. Operating within the biotechnology sector, the company impacts both healthcare and pharmaceutical industries by striving to improve the delivery and accessibility of treatments. By leveraging its proprietary technology, Matinas Biopharma plays a crucial role in the market by providing advanced solutions that could potentially reformulate how certain medications are administered, contributing to a broader goal of enhancing patient outcomes and quality of life.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2023 | $1M | — | -$24M | -$23M | — |
| 2022 | $3M | — | -$25M | -$21M | — |
| 2021 | $33,000 | — | -$25M | -$23M | — |
| 2020 | $158,333 | — | -$24M | -$22M | — |
| 2019 | $89,812 | — | -$19M | -$17M | — |
| 2018 | $119,750 | — | -$15M | -$14M | — |
| 2017 | $149,687 | — | -$17M | -$15M | — |
| 2016 | — | — | -$8M | -$8M | — |
| 2015 | $194,494 | — | -$10M | -$9M | — |
| 2014 | — | — | -$10M | -$10M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2023 | $25M | $6M | $19M | $5M | — |
| 2022 | $45M | $8M | $37M | $7M | — |
| 2021 | $61M | $9M | $52M | $21M | — |
| 2020 | $71M | $7M | $64M | $12M | — |
| 2019 | $40M | $7M | $33M | $22M | — |
| 2018 | $20M | $4M | $16M | $12M | — |
| 2017 | $14M | $4M | $11M | $7M | — |
| 2016 | $10M | $3M | $7M | $4M | — |
| 2015 | $8M | $2M | $6M | $3M | — |
| 2014 | $3M | $1M | $2M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$7M | — | — |
| 2024 | -$16M | — | — |
| 2023 | -$15M | $218,000 | -$15M |
| 2022 | -$19M | $892,000 | -$20M |
| 2021 | -$15M | $260,000 | -$15M |
| 2020 | -$17M | $5,749 | -$17M |
| 2019 | -$14M | $405,604 | -$14M |
| 2018 | -$10M | $535,916 | -$11M |
| 2017 | -$11M | $942,180 | -$12M |
| 2016 | -$6M | — | -$6M |
| 2015 | -$8M | $76,179 | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/MTNB)